DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong pipeline, FDA clearance for expanded trials, positive analyst sentiment, and undervaluation ahead of key trial readouts make it a compelling investment opportunity. Despite the lack of immediate trading signals and neutral technical indicators, the long-term growth potential outweighs short-term fluctuations.
The MACD is below 0 and negatively contracting, indicating a weak momentum. RSI is neutral at 54.021, and moving averages are converging, showing no clear trend. Key support is at 8.925, and resistance levels are at 10.102 and 10.465. Overall, the technical indicators suggest a neutral short-term outlook.
FDA clearance to expand the REGAIN study and add leading U.S. academic cancer centers.
Preliminary results show a 100% local disease control rate and a 67% complete response rate for Alpha-DaRT.
Analysts have raised price targets, with Barclays setting a $17 target and maintaining an Overweight rating.
Positive sentiment around the company's pipeline and trial progress.
Post-market price drop of -2.51%.
Lack of significant hedge fund or insider trading activity.
No immediate trading signals from AI Stock Picker or SwingMax.
Financial data is unavailable for detailed analysis. However, Q1 results showed an operating loss of $13.3M, with $80M in cash reserves, indicating sufficient liquidity to fund ongoing trials.
Analysts are broadly positive on Alpha Tau, with multiple firms raising price targets (e.g., Barclays to $17, Ladenburg to $14, H.C. Wainwright to $15) and maintaining Buy or Overweight ratings. The stock is seen as undervalued ahead of key trial readouts in H2 2026.
